You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib
|
|---|---|
| Published in |
BioDrugs, March 2019
|
| DOI | 10.1007/s40259-019-00337-6 |
| Pubmed ID | |
| Authors |
Tanja K. Eggersmann, Tom Degenhardt, Oleg Gluz, Rachel Wuerstlein, Nadia Harbeck |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 127 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 127 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 13% |
| Student > Bachelor | 14 | 11% |
| Researcher | 8 | 6% |
| Student > Postgraduate | 7 | 6% |
| Student > Master | 7 | 6% |
| Other | 17 | 13% |
| Unknown | 58 | 46% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 13% |
| Medicine and Dentistry | 16 | 13% |
| Biochemistry, Genetics and Molecular Biology | 12 | 9% |
| Agricultural and Biological Sciences | 5 | 4% |
| Immunology and Microbiology | 2 | 2% |
| Other | 9 | 7% |
| Unknown | 66 | 52% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 March 2019.
All research outputs
#18,673,707
of 23,136,540 outputs
Outputs from BioDrugs
#581
of 664 outputs
Outputs of similar age
#266,954
of 352,356 outputs
Outputs of similar age from BioDrugs
#9
of 12 outputs
Altmetric has tracked 23,136,540 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 664 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,356 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.